EGFR-TKI AFTER DISEASE PROGRESSION WITH CENTRAL NERVOUS SYSTEM METASTASIS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS

被引：0
|
作者：
Kasahara, Kazuo [1 ]
Sone, Takashi [1 ]
Shibata, Kazuhiko [2 ]
Shirasaki, Hiroki [3 ]
Kita, Toshiyuki [4 ]
Sakai, Asao [5 ]
Nishikawa, Shingo [6 ]
Yoneda, Taro [1 ]
Kimura, Hideharu [1 ]
机构：
[1] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[2] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[3] Fukui Ken Saiseika Hosp, Fukui, Japan
[4] Nho Kanazawa Med Ctr, Kanazawa, Ishikawa, Japan
[5] Keijyu Med Ctr, Nanao, Japan
[6] Kanazawa Social Insurance Hosp, Kanazawa, Ishikawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR tyrosine kinase inhibitor; EGFR mutation; Beyond Progressive Disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-045
引用
收藏
页码：S1210 / S1210
页数：1
相关论文
共 50 条
  • [31] Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer
    Fei Zhou
    Caicun Zhou
    Oncology and Translational Medicine, 2015, 1 (01) : 20 - 25
  • [32] REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Yamauchi, Hiroyoshi
    Nakayama, Masayuki
    Yamamoto, Shinichi
    Saito, Tatsuya
    Okuyama, Akiko
    Mato, Naoko
    Yamasawa, Hideaki
    Suzuki, Takuji
    Bando, Masashi
    Hagiwara, Koichi
    RESPIROLOGY, 2017, 22 : 242 - 242
  • [33] Osimertinib Delays but Not Prevents Central Nervous System Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhou, Y.
    Zhu, Z.
    Ni, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S591 - S591
  • [34] Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report
    Wang, Zhiyi
    Zhou, Pu
    Li, Guanghui
    ONCOLOGY LETTERS, 2016, 12 (01) : 356 - 360
  • [35] Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report
    Peng, Yanmei
    Cui, Huijuan
    Liu, Zhe
    Liu, Daiwei
    Liu, Fan
    Song, Yazhong
    Duan, Hua
    Qiu, Yuqin
    Li, Qiang
    ONCOTARGETS AND THERAPY, 2017, 10 : 2289 - 2295
  • [36] Continuing EGFR-TKI in Combination with Regional Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR(+) Non-Small Cell Lung Cancer
    Zhang, Jie
    Qi, Huiwei
    Wang, Sen
    Ni, Juan H.
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S524 - S524
  • [37] EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
    Tsai, Jeng-Shiuan
    Su, Po-Lan
    Yang, Szu-Chun
    Chang, Chao-Chun
    Lin, Chia-Ying
    Yen, Yi-Ting
    Tseng, Yau-Lin
    Lai, Wu-Wei
    Lin, Chien-Chung
    Su, Wu-Chou
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (09) : 1729 - 1739
  • [38] Continued EGFR-TKI With Concurrent Radiation Therapy to Improve Time to Progression in Patients with Locally Progressive Non-small Cell Lung Cancer After Front-Line EGFR-TKI Treatment
    Sun, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E724 - E724
  • [39] Evaluation of EGFR degradation as a mechanism of tumor evasion in EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells compared to EGFR-TKI sensitive cells
    Norma, Hernandez-Pedro Y.
    Giovanny, Soca-Chafre
    Mario, Orozco-Morales
    Pedro, Barrios-Bernal
    Oscar, Arrieta
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer
    Ge, Liangqing
    Shi, Ruizheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (07): : 10330 - 10339
12345